Compare Prudential Financial Inc (PRU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Twist Bioscience Corp — how do they compare? Prudential Financial Inc trades at $118.18 (market cap $40.97B), while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: Prudential Financial Inc is far larger — about 6.9× Twist Bioscience Corp's market cap, and Prudential Financial Inc pays a 4.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| PRU | TWST | |
|---|---|---|
Market Cap | $40.97B | $5.97B |
Sector | Financials | Health |
52-Week High | $119.07 | $102.88 |
52-Week Low | $92.00 | $24.16 |
Enterprise Value | $68.03B | $5.89B |
Dividend Yield | 4.75% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
